

PATENT ASSIGNMENT

Electronic Version v1.1  
Stylesheet Version v1.1

|                            |                                                                                                 |
|----------------------------|-------------------------------------------------------------------------------------------------|
| SUBMISSION TYPE:           | NEW ASSIGNMENT                                                                                  |
| NATURE OF CONVEYANCE:      | Confirmatory Grant of Security Interest in United States Patents (Exclusively Licensed Patents) |
| CONVEYING PARTY DATA       |                                                                                                 |
| Name                       | Execution Date                                                                                  |
| Endo Pharmaceuticals Inc.  | 10/16/2009                                                                                      |
| RECEIVING PARTY DATA       |                                                                                                 |
| Name:                      | JPMorgan Chase Bank, N.A., as Administrative Agent                                              |
| Street Address:            | 10 South Dearborn                                                                               |
| City:                      | Chicago                                                                                         |
| State/Country:             | ILLINOIS                                                                                        |
| Postal Code:               | 60603                                                                                           |
| PROPERTY NUMBERS Total: 83 |                                                                                                 |
| Property Type              | Number                                                                                          |
| Patent Number:             | 6326357                                                                                         |
| Patent Number:             | 6809081                                                                                         |
| Patent Number:             | 6794368                                                                                         |
| Patent Number:             | 6329347                                                                                         |
| Patent Number:             | 7125858                                                                                         |
| Patent Number:             | 6890911                                                                                         |
| Patent Number:             | 6455066                                                                                         |
| Patent Number:             | 6746689                                                                                         |
| Patent Number:             | 5776952                                                                                         |
| Application Number:        | 11361954                                                                                        |
| Patent Number:             | RE37355                                                                                         |
| Application Number:        | 11133190                                                                                        |
| Application Number:        | 10803187                                                                                        |
| Patent Number:             | 7361690                                                                                         |

501092480

PATENT  
REEL: 023928 FRAME: 0628

CH \$3320.00 6326357

|                     |          |
|---------------------|----------|
| Patent Number:      | 7168937  |
| Application Number: | 11774816 |
| Application Number: | 11334344 |
| Application Number: | 12118231 |
| Patent Number:      | 5709869  |
| Patent Number:      | 5411738  |
| Patent Number:      | 5589180  |
| Patent Number:      | 5601838  |
| Patent Number:      | 5472711  |
| Patent Number:      | 5478574  |
| Patent Number:      | 5330761  |
| Patent Number:      | 5135757  |
| Patent Number:      | 5399359  |
| Patent Number:      | 5169639  |
| Patent Number:      | 5399362  |
| Application Number: | 11545954 |
| Application Number: | 11546129 |
| Application Number: | 11546128 |
| Patent Number:      | 5128143  |
| Patent Number:      | 5399358  |
| Patent Number:      | 7276250  |
| Patent Number:      | 5846563  |
| Patent Number:      | 5512297  |
| Patent Number:      | 5554387  |
| Patent Number:      | 5455046  |
| Patent Number:      | 5667801  |
| Patent Number:      | 6136343  |
| Patent Number:      | 6726930  |
| Patent Number:      | 5662933  |
| Patent Number:      | 5958456  |
| Patent Number:      | 6048548  |
| Patent Number:      | 6709677  |
| Patent Number:      | 5773025  |
| Patent Number:      | 6245356  |
| Application Number: | 11891775 |

|                     |          |
|---------------------|----------|
| Application Number: | 12515429 |
| Application Number: | 61155371 |
| Patent Number:      | 6319913  |
| Patent Number:      | 6579865  |
| Patent Number:      | 7157097  |
| Patent Number:      | 5770559  |
| Patent Number:      | 5981474  |
| Patent Number:      | 6613358  |
| Patent Number:      | 5861174  |
| Patent Number:      | 6482435  |
| Patent Number:      | 5962501  |
| Patent Number:      | 5616603  |
| Patent Number:      | 5827871  |
| Patent Number:      | 5637611  |
| Patent Number:      | 5618948  |
| Patent Number:      | 5917054  |
| Patent Number:      | 6359146  |
| Patent Number:      | 5618947  |
| Patent Number:      | 5464864  |
| Application Number: | 10798780 |
| Patent Number:      | 5447729  |
| Patent Number:      | 6692767  |
| Patent Number:      | 5484608  |
| Patent Number:      | 6793934  |
| Patent Number:      | 5595004  |
| Patent Number:      | 5897876  |
| Patent Number:      | 6838093  |
| Patent Number:      | 5494915  |
| Patent Number:      | 5599936  |
| Patent Number:      | 5536263  |
| Patent Number:      | 5741510  |
| Patent Number:      | 6096333  |
| Patent Number:      | 6096334  |
| Patent Number:      | 6361790  |

**CORRESPONDENCE DATA**

Fax Number: (214)981-3400

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 214-981-3483

Email: dclark@sidley.com

Correspondent Name: Dusan Clark, Esq.

Address Line 1: Sidley Austin LLP

Address Line 2: 717 N. Harwood St., Suite 3400

Address Line 4: Dallas, TEXAS 75201

**ATTORNEY DOCKET NUMBER:**

36084-36730

**NAME OF SUBMITTER:**

Dusan Clark

**Total Attachments: 9**

source=Endo Patents#page1.tif

source=Endo Patents#page2.tif

source=Endo Patents#page3.tif

source=Endo Patents#page4.tif

source=Endo Patents#page5.tif

source=Endo Patents#page6.tif

source=Endo Patents#page7.tif

source=Endo Patents#page8.tif

source=Endo Patents#page9.tif

**CONFIRMATORY GRANT OF SECURITY INTEREST  
IN UNITED STATES PATENTS**

THIS CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Confirmatory Grant") is made effective as of October 16, 2009 by and from ENDO PHARMACEUTICALS INC., a Delaware corporation (the "Grantor"), to and in favor of JPMORGAN CHASE BANK, N.A., for itself and as Administrative Agent for the Secured Parties (as defined in the Credit Agreement referenced below) (in such capacities, the "Grantee").

WHEREAS, Endo Pharmaceuticals Holdings Inc. (the "Borrower"), the Lenders and the Grantee have entered into a Credit Agreement dated as of October 16, 2009 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement").

WHEREAS, the Grantor, along with certain other Subsidiaries of the Borrower, has guaranteed the repayment of the Secured Obligations pursuant to a Guaranty dated as of October 16, 2009 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Guaranty").

WHEREAS, the Grantor and certain Subsidiaries of the Borrower have entered into a Pledge and Security Agreement dated as of October 16, 2009 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement").

WHEREAS, the Grantor is the exclusive licensee of the patents listed on Exhibit A attached hereto (the "Patents"), which Patents are pending or registered with the United States Patent and Trademark Office.

WHEREAS, this Confirmatory Grant has been executed in conjunction with the security interest granted under the Security Agreement to the Grantee for the benefit of the Secured Parties. In the event that any provisions of this Confirmatory Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

1) Definitions. All capitalized terms not defined herein shall have the respective meaning given to them in the Credit Agreement.

2) The Security Interest.

(a) This Confirmatory Grant is made to secure the satisfactory performance and payment of (i) all the Secured Obligations and (ii) all of the obligations and liabilities of the Subsidiary Guarantors under the Guaranty. Upon the payment in full of all Secured Obligations (other than Unliquidated Obligations), the Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to the Grantor all reasonably requested instruments in writing releasing the security interest in the Patents acquired under the Security Agreement and this Confirmatory Grant.

(b) The Grantor hereby pledges and grants to the Grantee, on behalf of and for the benefit of the Secured Parties, a security interest in all of the Grantor's right, title and interest in and to the

patents and patent applications under and to the extent set forth in and permitted by the exclusive license to Grantor of such patents and patent applications.

3) Governing Law. **THIS CONFIRMATORY GRANT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.**

\*\*\*\*\*

IN WITNESS WHEREOF, the Grantor has executed this Confirmatory Grant effective as of the date first written above.


ENDO PHARMACEUTICALS INC.

By:   
Name: Caroline B. Manogue  
Title: Executive Vice President  
Chief Legal Officer and Secretary

STATE OF DELAWARE )  
NEW CASTLE COUNTY )

On February 5, 2010, before me, DENISE M. CRAIG, Notary Public, personally appeared CAROLINE MANOGUE, personally known to me to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument, the person, or the entity upon behalf of which the person acted, executed the instrument.

(SEAL)  
DENISE M. CRAIG  
NOTARY PUBLIC  
STATE OF DELAWARE  
My commission expires April 26, 2011

  
Notary Public, State of DELAWARE

My Commission Expires: 4/26/2011

Signature Page for  
Grant of Security Interest in United States Trademarks

PATENT  
REEL: 023928 FRAME: 0634

**CONFIRMATORY GRANT OF SECURITY INTEREST  
IN UNITED STATES PATENTS  
Exhibit A - SCHEDULE OF LICENSED PATENTS**

| <b>Title</b>                                                                                      | <b>Country</b> | <b>App. No.</b> | <b>App. Date</b> | <b>Patent No.</b> | <b>Issued</b> | <b>Owner</b>                |
|---------------------------------------------------------------------------------------------------|----------------|-----------------|------------------|-------------------|---------------|-----------------------------|
| Bacterial cell complex composition and method of use                                              | United States  | 09/129,312      | 5-Aug-98         | 6,326,357         | 4-Dec-01      | Bioniche Life Sciences Inc. |
| Chemotherapeutic composition and method                                                           | United States  | 09/857,332      | 17-Sep-01        | 6,809,081         | 26-Oct-04     | Bioniche Life Sciences Inc. |
| Composition and method for inducing apoptosis in prostate cancer cells                            | United States  | 09/937,643      | 10-Jan-02        | 6,794,368         | 21-Sep-04     | Bioniche Life Sciences Inc. |
| Composition and method for the treatment of bladder cancer                                        | United States  | 09/12,313       | 5-Aug-98         | 6,329,347         | 11-Dec-01     | Bioniche Life Sciences Inc. |
| Hyaluronic acid in the treatment of cancer                                                        | United States  | 10/168,327      | 29-Aug-02        | 7,125,858         | 24-Oct-06     | Bioniche Life Sciences Inc. |
| Method for the treatment of inflammation                                                          | United States  | 09/857,333      | 17-Sep-01        | 6,890,911         | 10-May-05     | Bioniche Life Sciences Inc. |
| Intradermal-penetration agents for topical local anesthetic administration                        | United States  | 09/523,652      | 10-Mar-00        | 6,455,066         | 24-Sep-02     | Epicept, Inc.               |
| Intradermal-Penetration Agents for Topical Local Anesthetic Administration                        | United States  | 10/201,901      | 25-Mar-02        | 6,746,689         | 6/8/2004      | Epicept Corporation         |
| Method and composition for topical therapy of back pain and muscle tension                        | United States  | 08/682,352      | 17-Jul-96        | 5,776,952         | 7-Jul-98      | Epicept Corporation**       |
| Phosphate salts of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxy-cyclohexane compounds  | United States  | 11/361,954      | 27-Feb-06        |                   |               | Grünenthal GmbH             |
| 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients         | United States  | 09/539,528      | 30-Mar-00        | RE 37,355         | 4-Sep-01      | Grünenthal GmbH             |
| Combination of selected analgesics and COX-II inhibitors                                          | United States  | 11/133,190      | 20-May-05        |                   |               | Grünenthal GmbH             |
| Combination of selected opioids with muscarine antagonists for treating urinary incontinence      | United States  | 10/803,187      | 18-Mar-04        |                   |               | Grünenthal GmbH             |
| Compositions and methods for the treatment of urinary incontinence                                | United States  | 10/978,565      | 2-Nov-04         | 7,361,690         | 22-Apr-08     | Grünenthal GmbH             |
| Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives | United States  | 10/203,031      | 4-Nov-02         | 7,168,937         | 30-Jan-07     | Grünenthal GmbH             |

Exhibit A



| Title                                                                                                                                          | Country       | App. No.   | App. Date | Patent No. | Issued    | Owner                       |
|------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------|-----------|------------|-----------|-----------------------------|
| Method of Inhibiting Inflammatory pain                                                                                                         | United States | 11/774,816 | 9-Sep-07  |            |           | Grünenthal GmbH             |
| Pharmaceutical composition containing 5-dimethylaminomethyl-1,3-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release  | United States | 11/334,344 | 19-Jan-06 |            |           | Grünenthal GmbH             |
| Use of Axomadol for Treatment of Arthrosis Pain                                                                                                | United States | 12/118,231 | 9-May-08  |            |           | Grünenthal GmbH             |
| Method for treating nerve injury pain associated with shingles                                                                                 | United States | 08/773,529 | 23-Dec-96 | 5,709,869  | 20-Jan-98 | Hind Health Care, Inc.      |
| Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine | United States | 08/198,223 | 16-Feb-94 | 5,411,738  | 2-May-95  | Hind Health Care, Inc.      |
| Method for treating nerve injury pain associates with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine | United States | 08/611,168 | 5-Mar-96  | 5,589,180  | 31-Dec-96 | Hind Health Care, Inc.      |
| Method for treating pain associated with herpes-zoster and post-herpetic neuralgia                                                             | United States | 07/526,771 | 18-May-90 | 5,601,838  | 11-Feb-97 | Hind Health Care, Inc.      |
| Agglomerated hydrophilic complexes with multi-phasic release characteristics                                                                   | United States | 07/922,312 | 30-Jul-92 | 5,472,711  | 5-Dec-95  | Penwest Pharmaceuticals Co. |
| Agglomerated hydrophilic complexes with multi-phasic release characteristics                                                                   | United States | 08/094,504 | 20-Jul-93 | 5,478,574  | 26-Dec-95 | Penwest Pharmaceuticals Co. |
| Bioadhesive tablet for non-systemic use products                                                                                               | United States | 08/011,428 | 29-Jan-93 | 5,330,761  | 19-Jul-94 | Penwest Pharmaceuticals Co. |
| Compressible sustained release solid dosage forms                                                                                              | United States | 07/642,070 | 16-Jan-91 | 5,135,757  | 4-Aug-92  | Penwest Pharmaceuticals Co. |
| Controlled release oxybutynin formulations                                                                                                     | United States | 08/206,416 | 4-Mar-94  | 5,399,359  | 21-Mar-95 | Penwest Pharmaceuticals Co. |
| Controlled release verapamil tablets                                                                                                           | United States | 07/736,031 | 25-Jul-91 | 5,169,639  | 8-Dec-92  | Penwest Pharmaceuticals Co. |
| Once-a-day metoprolol oral dosage form                                                                                                         | United States | 08/232,719 | 25-Apr-94 | 5,399,362  | 21-Mar-95 | Penwest Pharmaceuticals Co. |
| Robust sustained release formulations of oxymorphone                                                                                           | United States | 11/545,954 | 10-Oct-06 |            |           | Penwest Pharmaceuticals Co. |
| Robust sustained release formulations of oxymorphone                                                                                           | United States | MAILED     | 10-Oct-06 |            |           | Penwest Pharmaceuticals Co. |
| Robust sustained release formulations of oxymorphone                                                                                           | United States | 11/546,129 | 10-Oct-06 |            |           | Penwest Pharmaceuticals Co. |

| Title                                                                           | Country       | App. No.   | App. Date  | Patent No. | Issued    | Owner                       |
|---------------------------------------------------------------------------------|---------------|------------|------------|------------|-----------|-----------------------------|
| Robust sustained release formulations of oxymorphone and methods of use thereof | United States | 11/546,128 | 10-Oct-06  |            |           | Penwest Pharmaceuticals Co. |
| Robust sustained release formulations of oxymorphone and methods of use thereof | United States | MAILED     | 10-Oct-06  |            |           | Penwest Pharmaceuticals Co. |
| Sustained release excipient and tablet formulation                              | United States | 07/491,189 | 9-Mar-90   | 5,128,143  | 7-Jul-92  | Penwest Pharmaceuticals Co. |
| Sustained release formulations for 24 hour release of metoprolol                | United States | 08/151,272 | 12-Nov-93  | 5,399,358  | 21-Mar-95 | Penwest Pharmaceuticals Co. |
| Sustained release formulations of oxymorphone                                   | United States | 10/189,932 | 3-Jul-02   | 7,276,250  | 10/2/2007 | Penwest Pharmaceuticals Co. |
| Sustained release formulations of oxymorphone                                   | United States | 10/190,383 | 3-Jul-02   | ABANDONED  |           | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems for insoluble drugs           | United States | 08/843,573 | 18-Apr-97  | 5,846,563  | 8-Dec-98  | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems for insoluble drugs           | United States | 08/447,235 | 22-May-95  | 5,512,297  | 30-Apr-96 | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems for insoluble drugs           | United States | 08/447,236 | 22-May-95  | 5,554,387  | 10-Sep-96 | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems for insoluble drugs           | United States | 08/118,924 | 9/9/1993   | 5,455,046  | 10/3/1995 | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems for insoluble drugs           | United States | 08/651,901 | 21-May-96  | 5,667,801  | 16-Sep-97 | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems for insoluble drugs           | United States | 09/207,298 | 8-Dec-98   | 6,136,343  | 24-Oct-00 | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems for insoluble drugs           | United States | 09/654,691 | 5-Sep-00   | 6,726,930  | 27-Apr-04 | Penwest Pharmaceuticals Co. |
| Controlled release formulation (albuterol)                                      | United States | 08/553,008 | 11-03-1995 | 5,662,933  | 02-Sep-97 | Penwest Pharmaceuticals Co. |
| Controlled release formulation (albuterol)                                      | United States | 08/886,496 | 07-01-1997 | 5,958,456  | 28-Sep-99 | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems-amorphous drugs               | United States | 09/106,438 | 06-29-1998 | 6,048,548  | 11-Apr-00 | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems-amorphous drugs               | United States | 09/879,296 | 06-12-2001 | 6,709,677  | 23-Mar-04 | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems-amorphous drugs               | United States | 08/634,295 | 04-18-1996 | 5,773,025  | 30-Jun-98 | Penwest Pharmaceuticals Co. |
| Sustained release heterodisperse hydrogel systems-amorphous drugs               | United States | 09/498,448 | 02-04-2000 | 6,245,356  | 12-Jun-01 | Penwest Pharmaceuticals Co. |

| Title                                                                                                                      | Country       | App. No.   | App. Date | Patent No. | Issued    | Owner                                    |
|----------------------------------------------------------------------------------------------------------------------------|---------------|------------|-----------|------------|-----------|------------------------------------------|
| Sustained release formulations of oxymorphone                                                                              | United States | 11/891,775 | 8/13/2007 |            |           | Penwest Pharmaceuticals Co.              |
| Methods, compositions, and kits for treating pain and pruritis                                                             | United States | 12/515,429 | 19-May-09 |            |           | President and Fellows of Harvard College |
| Methods, compositions, and kits for treating surgical, wound, neuropathic, and inflammatory pain                           | United States | 61/155,371 | 25-Feb-09 |            |           | President and Fellows of Harvard College |
| Penetration enhancing and irritation reducing systems                                                                      | United States | 09/189,090 | 9-Nov-98  | 6,319,913  | 20-Nov-01 | Strakan International Limited            |
| Penetration enhancing and irritation reducing systems                                                                      | United States | 09/963,287 | 24-Sep-01 | 6,579,865  | 17-Jun-03 | Strakan International Limited            |
| Penetration enhancing and irritation reducing systems                                                                      | United States | 10/389,715 | 12-Mar-03 | 7,157,097  | 2-Jan-07  | Strakan International Limited            |
| Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same | United States | 08/473,008 | 6-Jun-95  | 5,770,559  | 23-Jun-98 | Regents of the University of Colorado    |
| Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same | United States | 09/098,791 | 17-Jun-98 | 5,981,474  | 9-Nov-99  | Regents of the University of Colorado    |
| Sustained-release composition including amorphous polymer                                                                  | United States | 09/877,330 | 7-Jun-01  | 6,613,358  | 2-Sep-03  | Regents of the University of Colorado    |
| Temperature sensitive gel for sustained delivery of protein drugs                                                          | United States | 08/679,199 | 12-Jul-96 | 5,861,174  | 19-Jan-99 | Regents of the University of Colorado    |
| Temperature sensitive gel for sustained delivery of protein drugs                                                          | United States | 09/232,288 | 15-Jan-99 | 6,482,435  | 19-Nov-02 | Regents of the University of Colorado    |
| Enantiomer of carbazole derivative as 5-HT <sub>1</sub> -like agonists                                                     | United States | 08/770,926 | 23-Dec-96 | 5,962,501  | 5-Oct-99  | Venalis Development Limited              |
| Enantiomers of carbazole derivatives as 5-HT <sub>1</sub> -like agonists                                                   | United States | 08/451,898 | 26-May-95 | 5,616,603  | 1-Apr-97  | Venalis Development Limited              |
| Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT <sub>1</sub> agonist use thereof                                         | United States | 08/442,720 | 17-May-95 | 5,827,871  | 27-Oct-98 | Venalis Development Limited              |
| Medicaments                                                                                                                | United States | 08/442,719 | 15-May-95 | 5,637,611  | 10-Jun-97 | Venalis Development Limited              |
| Process for preparing an enantiomer of carbazole derivative                                                                | United States | 08/451,846 | 26-May-95 | 5,618,948  | 8-Apr-97  | Venalis Development Limited              |

| Title                                                                                                    | Country       | App. No.    | App. Date | Patent No. | Issued    | Owner                         |
|----------------------------------------------------------------------------------------------------------|---------------|-------------|-----------|------------|-----------|-------------------------------|
| Process for preparing enantiomers of carbazole derivatives as 5-HT <sub>1</sub> -like agonists           | United States | 08/781,990  | 6-Jan-97  | 5,917,054  | 29-Jun-99 | Venalis Development Limited   |
| Process for the production of R-(+)-6-carboxamido-3-N-methylamino-1,2,3,4-tetrahydrocarbazole            | United States | 09/689,661  | 13-Oct-00 | 6,359,146  | 19-Mar-02 | Venalis Development Limited   |
| Process of preparing enantiomers of carbazole derivatives                                                | United States | 08/446,655  | 16-Dec-93 | 5,618,947  | 8-Apr-97  | Venalis Development Limited   |
| Use of tetrahydrocarbazone derivatives as 5-HT <sub>1</sub> receptor agonists                            | United States | 08/167,846  | 23-Dec-93 | 5,464,864  | 7-Nov-95  | Venalis Development Limited   |
| Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | United States | 10/798,780  | 12-Mar-04 |            |           | Bayer-Schering (Schering AG)  |
| Multilamellar Drug Delivery System                                                                       | United States | 08/224,340  | 4/7/1994  | 5,447,729  | 9/5/1995  | Supernus Pharmaceuticals, Inc |
| Solid Solution Beadlet                                                                                   | United States | 09/156,464  | 9/18/1998 | 6,692,767  | 2/7/2004  | Supernus Pharmaceuticals, Inc |
| Sustained-Release Drug Delivery System                                                                   | United States | 08/218,757  | 3/28/1994 | 5,484,608  | 1/16/1996 | Supernus Pharmaceuticals, Inc |
| Solid oral dosage form                                                                                   | United States | 09/457,248  | 12/8/1999 | 6,793,934  | 9/21/2004 | Supernus Pharmaceuticals, Inc |
| Emulsified Drug Delivery System                                                                          | United States | 08/424,521  | 8/28/1995 | 5,595,004  | 9/14/1999 | Supernus Pharmaceuticals, Inc |
| Emulsified Drug Delivery System                                                                          | United States | 08/9879,994 | 6/20/1997 | 5,897,876  | 4/27/2009 | Supernus Pharmaceuticals, Inc |
| System for the Osmotic Delivery of Pharmaceutically Active Agents                                        | United States | 09/872,173  | 6/1/2001  | 6,838,093  | 1/4/2005  | Supernus Pharmaceuticals, Inc |
| New isoindolinone derivative, its preparation and the pharmaceutical compositions which contain it       | United States | 08/286,294  | 8/5/1994  | 5,494,915  | 2/27/1996 | Aventis Pharma S.A.           |
| New isoindolinone derivative, its preparation and the pharmaceutical compositions which contain it       | United States | 08/476,749  | 6/7/1995  | 5,599,936  | 2/4/1997  | Aventis Pharma S.A.           |
| Non-Occlusive Adhesive Patch for Applying Medication to the Skin                                         | United States | 08/291,982  | 30-Mar-94 | 5,536,263  | 16-Jul-96 | LecTec Corporation            |
| Adhesive patch for applying analgesic medication to the skin                                             | United States | 08/629,191  | 8-Apr-96  | 5,741,510  | 21-Apr-98 | LecTec Corporation            |

| <b>Title</b>                                                         | <b>Country</b> | <b>App. No.</b> | <b>App. Date</b> | <b>Patent No.</b> | <b>Issued</b> | <b>Owner</b>       |
|----------------------------------------------------------------------|----------------|-----------------|------------------|-------------------|---------------|--------------------|
| Method of forming adhesive patch for applying medication to the skin | United States  | 08/947,089      | 8-Oct-97         | 6,096,333         | 1-Aug-00      | LecTec Corporation |
| Method of forming adhesive patch for applying medication to the skin | United States  | 09/211,222      | 14-Dec-98        | 6,096,334         | 1-Aug-00      | LecTec Corporation |
| Method of forming adhesive patch for applying medication to the skin | United States  | 09/629,783      | 31-Jul-00        | 6,361,790         | 26-Mar-02     | LecTec Corporation |

\*\* Recorded in name of American Pharmed Labs, Inc.